keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical BCG

keyword
https://www.readbyqxmd.com/read/27903467/arterio-cutaneous-fistula-associated-with-bilateral-femoral-pseudoaneurysms-caused-by-bacillus-calmette-gu%C3%A3-rin-apropos-of-a-case-and-review-of-literature
#1
Álvaro Torres-Blanco, Francisco Gómez-Palonés, Gemma Edo-Fleta
Vascular complications of intravesical instillation of bacillus Calmette-Guérin (BCG) are rare. BCG is an attenuated strain of Mycobacterium bovis (M. Bovis) that was initially developed for vaccination against tuberculosis, but it has also been used as an adjuvant treatment for bladder transitional carcinoma. We report a patient with a history of instillation of BCG two years before, who underwent surgical treatment of 2 pseudoaneurysms. The first, located in the left superficial femoral artery (SFA), was resected and the artery was ligated because he had a history of femoropopliteal occlusion...
November 26, 2016: Annals of Vascular Surgery
https://www.readbyqxmd.com/read/27893591/endophthalmitis-in-a-patient-treated-with-bacillus-calmette-gu%C3%A3-rin-immunotherapy
#2
Julie Vadboncoeur, Sébastien Olivier, Hafid Soualhine, Annie-Claude Labbé, Marie-Lyne Bélair
BACKGROUND: Intravesical Bacillus Calmette-Guérin (BCG) instillation has become one of the mainstays of adjunctive therapy in the treatment of superficial bladder cancer. Ophthalmologic complications are rare, but few cases are reported in the literature. METHODS: Retrospective observational case report. RESULTS: The authors report a case of unilateral Mycobacterium bovis BCG endophthalmitis after intravesical BCG instillations. Despite appropriate systemic antituberculous and corticosteroid therapy, the patient almost completely lost sight in the affected eye...
November 23, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27885456/-intravesical-radioimmunotherapy-of-carcinoma-in-situ-of-the-urinary-bladder-after-bcg-failure
#3
M E Autenrieth, T Horn, F Kurtz, K Nguyen, A Morgenstern, F Bruchertseifer, M Schwaiger, M Blechert, C Seidl, R Senekowitsch-Schmidtke, J E Gschwend, K Scheidhauer
BACKGROUND: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. OBJECTIVES: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. MATERIALS AND METHODS: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled...
November 24, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27884539/intravesical-chemotherapy-use-after-radical-nephroureterectomy-a-national-survey-of-urologic-oncologists
#4
Diane D Lu, Stephen A Boorjian, Jay D Raman
: To determine the use of prophylactic intravesical chemotherapy (pIVC) following radical nephroureterectomy (RNU) and barriers to utilization in a survey study of urologic oncologists. METHODS: A survey instrument was constructed, which queried respondents on professional experience, practice environment, pIVC use, and reasons for not recommending pIVC when applicable. The survey was electronically distributed to members of the Society of Urologic Oncology over an 8-week period...
November 21, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27846935/-ccafu-french-national-guidelines-2016-2018-on-bladder-cancer
#5
M Rouprêt, Y Neuzillet, A Masson-Lecomte, P Colin, E Compérat, F Dubosq, N Houédé, S Larré, G Pignot, P Puech, M Roumiguié, E Xylinas, A Méjean
OBJECTIVE: The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumour...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27800054/administration-of-mycobacterium-phlei-cell-wall-nucleic-acid-complex-in-the-immediate-postoperative-period-for-the-treatment-of-non-muscle-invasive-bladder-cancer
#6
Álvaro Morales
INTRODUCTION: This review sought to investigate the safety of intravesical administration of Mycobacterium phlei cell wall-nucleic acid (MCNA) in the immediate postoperative period after biopsy/resection for non-muscle-invasive bladder cancer (NMIBC). METHODS: Patients with NMIBC who failed bacillus Calmette-Guérin (BCG) therapy and at high risk of recurrence and progression participated in this study. Treatment involved an induction phase of six weeks and maintenance of three weekly instillations every six months for two years...
September 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27788495/evaluating-the-efficacy-and-safety-of-intravesical-chemotherapies-for-non-muscle-invasive-bladder-cancer-a-network-meta-analysis
#7
Chuanjun Zhuo, Xubin Li, Hongqing Zhuang, Shunli Tian, Hailong Cui, Ronghuan Jiang, Chuanxin Liu, Ran Tao, Xiaodong Lin
Various intravesical therapies have been introduced into clinical practices for controlling non-muscle invasive bladder cancer (NMIBC). However, evidence with respect to the efficacy and safety of those intravesical therapies is very limited. Hence, we present a network meta-analysis in order to address this limitation in the current literature. The primary outcomes were the risk of tumor recurrence (TR), tumor progression (TP) and disease-specific mortality (DM). Secondary outcomes included the risk of fever, cystitis and haematuria...
October 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27768213/radiofrequency-induced-thermo-chemotherapy-effect-rite-for-non-muscle-invasive-bladder-cancer-treatment-current-role-and-perspectives
#8
Renzo Colombo, Hans van Valenberg, Marco Moschini, Johannes A Witjes
OBJECTIVE: An updated review of intravesical radiofrequency (RF)-induced thermo-chemotherapy effect (RITE) for NMIBC with regard to efficacy, adverse events (AEs) and perspectives. EVIDENCE ACQUISITION: An extensive and sensitive search for RF-induced chemo-hyperthermia in Medline, Embase, Cochrane and ClinicalTrials.gov databases was performed. A table of published clinical trials up to 2016 was constructed. No meta-analysis could be performed on the basis of new papers...
October 4, 2016: Urologia
https://www.readbyqxmd.com/read/27761190/left-anterior-descending-coronary-artery-and-multiple-peripheral-mycotic-aneurysms-due-to-mycobacterium-bovis-following-intravesical-bacillus-calmette-guerin-therapy-a-case-report
#9
Petar Duvnjak, Mario Laguna
The use of live attenuated intravesicular Bacillus Calmette-Guerin (BCG) therapy is a generally accepted safe and effective method for the treatment of superficial transitional cell carcinoma (TCC) of the bladder. Although rare, < 5% of patient's treated with intravesicular BCG therapy may develop potentially serious complications, including localized infections to the genitourinary tract, mycotic aneurysms and osteomyelitis. We present here a case of a 63-year-old male who developed left coronary and multiple peripheral M...
August 2016: Journal of Radiology Case Reports
https://www.readbyqxmd.com/read/27750214/genomic-characterization-of-high-risk-non-muscle-invasive-bladder-cancer
#10
Joshua J Meeks, Benedito A Carneiro, Sachin G Pai, Daniel T Oberlin, Alfred Rademaker, Kyle Fedorchak, Sohail Balasubramanian, Julia Elvin, Nike Beaubier, Francis J Giles
The genetic mechanisms associated with progression of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have not been described. We conducted selective next-generation sequencing (NGS) of HR-NMIBC and compared the genomic profiles of cancers that responded to intravesical therapy and those that progressed to muscle-invasive or advanced disease. DNA was extracted from paraffin-embedded sections from 25 HR-NMIBCs (22 with T1HG; 3 with TaHG with or without carcinoma in situ). Ten patients with HR-NMIBC developed progression (pT2+ or N+) ("progressors")...
October 14, 2016: Oncotarget
https://www.readbyqxmd.com/read/27716887/intravesical-electro-osmotic-administration-of-mitomycin-c
#11
Savino M Di Stasi, Cristian Verri, Francesco Celestino, Francesco De Carlo, Vincenzo Pagliarulo
Bladder cancer is very common and most cases are diagnosed as nonmuscle invasive disease, which is characterized by its propensity to recur and progress. Intravesical therapy is used to delay recurrence and progression, while cystectomy is reserved for patients who are refractory to transurethral resection and intravesical therapy. There is an increasing interest in methods to enhance the delivery of intravesical chemotherapeutic agents to improve efficacy. In vitro and in vivo studies demonstrated that electro-osmosis of mitomycin C (MMC) is more effective in delivering this drug into the urothelium, lamina propria, and superficial muscle layers of the bladder wall than is passive transport...
October 4, 2016: Urologia
https://www.readbyqxmd.com/read/27716885/mitomycin-c-from-birth-to-adulthood
#12
Vincenzo Serretta, Cristina Scalici Gesolfo, Vincenza Alonge, Fabrizio Di Maida, Giovanni Caruana
Mitomycin C (MMC) intravesical therapy for "superficial" papillary bladder tumors was firstly introduced in the early seventies with promising results. In the following years, several pharmacokinetic studies investigated its mechanism of action to optimize the intravesical administration. Numerous studies confirmed thereafter both the ablative and the prophylactic efficacy and the low toxicity of MMC when intravesically given. In 1984, a complete response rate of 42% in 60 patients not responsive to thiotepa was reported with intravesical MMC at the dose of 40 mg diluted in 40 ml for 8 weeks...
October 4, 2016: Urologia
https://www.readbyqxmd.com/read/27712914/-intravesical-instillations-in-non-muscle-invasive-bladder-cancer-nmibc-prospects-for-thermochemotherapy
#13
J Irani
: Non-muscle-invasive bladder cancer (NMIBC) is characterised by a high risk of recurrence when performing only a transurethral resection of the bladder (TURB). Intravesical instillations are performed postoperatively to decrease the rate of recurrence. The standard agents currently used are Mitomycin-C (MMC) or bacillus Calmette-Guérin (BCG). In order to further enhance the efficacy of the adjuvant treatments and/or diminish their side effects, alternative treatments are studied. Intravesical MMC combined with hyperthermia could be an interesting alternative active treatment for intermediate- and possibly high-risk NMIBC, and has been investigated in the past years...
October 3, 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27701987/efficacy-and-safety-of-bladder-hydrodistension-for-decreased-bladder-capacity-induced-by-intravesical-bcg-therapy
#14
Kazuyuki Numakura, Norihiko Tsuchiya, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Tomonori Habuchi
OBJECTIVE: Intravesical BCG therapy is widely used for the treatment of high-risk, non-muscle-invasive bladder cancer. Among various reported side-effects, decreased bladder capacity is a serious side-effect that significantly worsens patients' quality of life. This article reports the efficacy and safety of bladder hydrodistension (BHD) in six patients with seriously decreased bladder capacity caused by BCG treatment. METHODS: Six patients with low bladder capacity (<100 ml in voiding diaries) and complaint of grade 3 irritative symptoms were diagnosed with decreased bladder capacity and treated with BHD...
October 5, 2016: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/27676732/total-hip-arthroplasty-infection-due-to-mycobacterium-bovis-after-bcg-therapy
#15
Alban Fouasson-Chailloux, Benoit Metayer, Pierre Menu, Lydie Khatchatourian, Joelle Glemarec, Marc Dauty
OBJECTIVE: The loosening of total joint replacement is a frequent complication after total hip arthroplasty (THA). Septic osteolysis should always be feared. We report here a rare case of hip arthroplasty infection due to Mycobacterium bovis after Bacillus Calmette-Guerin (BCG) therapy in a context of bladder cancer. OBSERVATIONS: A 70-year-old man was referred to the department of rheumatology in September 2015, because of a total functional disability of the left lower limb...
September 2016: Annals of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/27647081/mitomycin-c-new-strategies-to-improve-efficacy-of-a-well-known-therapy
#16
Mauro Ragonese, Marco Racioppi, Pier Francesco Bassi, Luca Di Gianfrancesco, Niccolò Lenci, Alessio Filianoti, Salvatore M Recupero
Mitomycin C (MMC) as an intravesical chemotherapeutic agent is a well-known option for treatment of nonmuscle invasive bladder cancer (NMIBC) recurrence; it is probably the most commonly used agent given its low rate of side effects and its efficacy.Both the American Urologic Association (AUA) and European Association of Urology (EAU) consider MMC as a standard treatment for immediate single-dose postoperative treatment and for adjuvant therapy in low and intermediate-risk NMIBC.Despite the popularity of this agent in the treatment of NMIBCs, many questions regarding the optimal approach to MMC therapy remain unanswered and the schedule widely used is empirical...
October 4, 2016: Urologia
https://www.readbyqxmd.com/read/27617552/failure-of-bacillus-calmette-gu%C3%A3-rin-therapy-in-non-muscle-invasive-bladder-cancer-definition-and-treatment-options
#17
J Gual Frau, J Palou, O Rodríguez, R Parada, A Breda, H Villavicencio
UNLABELLED: Adjuvant intravesical bacillus Calmette- Guérin (BCG) therapy is the standard conservative adjuvant treatment and the most effective regimen for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The term "BCG failure" is generally used to refer to recurrence or progression following BCG therapy, as experienced by many patients. However, the term has been defined inconsistently, and several studies have indicated that patients with a particular pattern of BCG failure have a worse prognosis...
September 2016: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/27614759/intravesical-treatment-for-interstitial-cystitis-painful-bladder-syndrome-a-network-meta-analysis
#18
Wei Zhang, Xiaojing Deng, Chunyu Liu, Xu Wang
INTRODUCTION AND HYPOTHESIS: Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic inflammatory condition of the submucosal and muscular layers of the bladder. So far, there is no effective and targeted treatment strategy for IC/PBS. This study aimed to assess the efficacy and safety of intravesical instillation treatment in IC/PBS patients. METHODS: We searched various databases up to October 2015. A network meta-analysis was performed to compare global response assessment (GRA) for different treatment strategies, including botulinum toxin A (BoNTA), bacillus Calmette-Guerin (BCG), resiniferatoxin (RTX), lidocaine, chondroitin sulfate (CS), oxybutynin, and pentosan polysulfate (PPS)...
September 10, 2016: International Urogynecology Journal
https://www.readbyqxmd.com/read/27563657/immunobiology-and-immunotherapy-in-genitourinary-malignancies
#19
REVIEW
Marinos Tsiatas, Petros Grivas
Immunotherapy has traditionally been a critical component of the cancer treatment armamentarium in genitourinary (GU) cancers. It has an established role in the management of carefully selected patients with metastatic renal cell carcinoma (RCC) [e.g., high dose interleukin-2 (IL-2)] and non-muscle invasive bladder cancer (NMIBC) [e.g., intravesical Bacillus Calmette-Guérin (BCG)]. In 2010, the sipuleucel-T vaccine was approved by the FDA for the management of metastatic castration-resistant prostate cancer (mCRPC), based on a phase III trial showing overall survival (OS) benefit compared to placebo...
July 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27559301/disseminated-mycobacterium-bovis-infection-complicating-intravesical-bcg-instillation-for-the-treatment-of-superficial-transitional-cell-carcinoma-of-the-bladder
#20
Fatehi Elzein, Nada Albogami, Mustafa Saad, Nazik El Tayeb, Abdullah Alghamdi, Ghaleb Elyamany
BACKGROUND: Intravesical instillation of Bacillus Calmette-Guérin (BCG) remains a first-line treatment for superficial transitional cell carcinoma of the bladder. Although its use is relatively safe, severe complications such as granulomatous hepatitis, osteomyelitis, pneumonitis, and sepsis occur in few patients. Complications of intravesical instillation of BCG can be local or systemic, with early or late presentation. CASE PRESENTATION: Here, we report an 88-year-old man who developed fever, rigors, and episodes of syncope following fourth intravesical BCG instillation for the treatment of superficial transitional cell carcinoma of the bladder...
2016: Clinical Medicine Insights. Case Reports
keyword
keyword
7101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"